

Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2009-2019, Louisiana

Primary Site ¹	All Race			White					Black		
	Total	Male	Female	Total	Male	Female			Total	Male	Female
All Sites	64.0%	63.7%	64.4%	65.7%	65.2%	↑	66.3%	↑	59.9%	60.2%	59.6%
Oral Cavity and Pharynx	60.7%	60.7%	60.6%	65.7%	66.6%	↑	63.1%	↑	43.2%	40.2%	50.8%
Lip	83.3%	83.8%	76.9%	82.9%	83.6%		76.2%		90.7%	89.6%	100.0%
Tongue	63.0%	63.3%	61.8%	68.4%	69.2%	↑	66.1%	↑	35.3%	33.1%	40.7%
Salivary Gland	70.6%	63.9%	80.2%	66.6%	61.4%		76.3%		80.2%	71.8%	86.9%
Floor of Mouth	48.8%	47.8%	50.6%	53.8%	52.6%	↑	55.3%	↑	36.5%	39.0%	22.5%
Gum and Other Mouth	54.9%	54.5%	55.5%	57.3%	57.9%		56.7%		48.7%	47.1%	50.8%
Nasopharynx	57.3%	55.9%	61.7%	59.6%	59.1%		59.5%		47.0%	47.1%	45.7%
Tonsil	70.1%	71.5%	62.6%	74.4%	75.8%	↑	66.6%	↑	51.1%	52.5%	43.9%
Oropharynx	42.1%	43.9%	36.7%	48.9%	52.7%	↑	38.6%		23.9%	21.2%	30.5%
Hypopharynx	31.4%	29.3%	41.3%	39.9%	38.1%	↑	47.8%		18.4%	16.5%	30.2%
Other Oral Cavity and Pharynx	45.5%	45.7%	45.3%	56.4%	58.2%	↑	49.2%		20.8%	12.9%	39.9%
Digestive System	43.2%	40.4%	47.0%	44.8%	42.4%	↑	48.1%	↑	40.3%	36.4%	45.2%
Esophagus	19.3%	17.2%	27.0%	21.0%	18.8%	↑	30.7%		14.8%	12.1%	21.6%
Stomach	30.7%	27.9%	35.3%	32.3%	30.3%	↑	36.1%		29.0%	25.4%	34.1%
Small Intestine	70.3%	71.5%	69.0%	72.4%	71.1%		73.7%	↑	66.4%	70.6%	62.6%
Colon and Rectum	62.8%	62.1%	63.6%	64.7%	64.6%	↑	64.9%	↑	59.1%	56.8%	61.3%
Colon excluding Rectum	62.3%	62.1%	62.6%	64.6%	64.6%	↑	64.7%	↑	58.0%	57.1%	58.9%
Cecum	61.6%	62.4%	60.9%	64.1%	63.8%		64.1%	↑	57.0%	59.0%	55.6%
Appendix	77.7%	78.9%	76.4%	82.0%	84.8%	↑	79.9%	↑	65.2%	66.2%	64.1%
Ascending Colon	64.5%	62.0%	66.7%	66.0%	64.0%		67.8%		62.8%	59.2%	65.4%
Hepatic Flexure	63.0%	63.9%	62.0%	63.6%	65.1%		61.6%		61.4%	61.5%	60.7%
Transverse Colon	61.7%	60.3%	63.0%	64.0%	64.6%	↑	62.9%		56.8%	51.4%	62.2%
Splenic Flexure	64.5%	65.8%	62.4%	63.6%	62.2%		64.7%		65.2%	69.9%	60.5%
Descending Colon	62.4%	62.0%	62.6%	64.6%	66.2%		62.6%		58.9%	55.6%	61.8%
Sigmoid Colon	65.1%	65.2%	64.9%	67.3%	67.4%	↑	67.2%	↑	60.0%	60.1%	60.0%
Large Intestine, NOS	28.4%	30.1%	26.4%	29.3%	32.9%		24.8%		26.8%	25.0%	28.6%
Rectum and Rectosigmoid Junction	64.0%	62.2%	66.4%	65.0%	64.7%	↑	65.4%		61.7%	56.4%	68.5%
Rectosigmoid Junction	59.0%	58.2%	60.2%	61.7%	62.6%	↑	60.5%		52.6%	47.6%	58.8%
Rectum	65.3%	63.3%	68.1%	65.9%	65.3%	↑	66.8%		63.9%	58.4%	70.7%
Anus, Anal Canal and Anorectum	68.1%	58.1%	75.1%	71.2%	61.4%		77.0%		58.5%	51.2%	66.3%
Liver and Intrahepatic Bile Duct	16.7%	15.8%	19.6%	17.7%	16.8%	↑	20.4%		14.0%	13.3%	17.0%
Liver	17.6%	16.5%	21.9%	19.0%	17.8%	↑	23.3%		14.5%	13.5%	18.5%
Intrahepatic Bile Duct	6.2%	3.9%	8.3%	6.4%	1.8%		9.5%		6.0%	6.6%	0.0%
Gallbladder	18.3%	14.5%	20.1%	18.3%	14.9%		20.0%		17.3%	14.7%	18.4%
Other Biliary	15.8%	13.1%	18.3%	15.7%	12.5%		19.6%		14.7%	12.3%	15.1%
Pancreas	8.6%	8.2%	9.0%	8.8%	8.5%	↑	9.1%		7.8%	6.7%	8.9%
Retroperitoneum	50.3%	40.6%	57.7%	48.1%	39.1%		57.3%		52.7%	37.1%	58.9%
Peritoneum, Omentum and Mesentery	27.4%	0.0%	29.7%	29.0%	0.0%		31.1%		21.3%	0.0%	24.4%
Other Digestive Organs	11.6%	10.9%	12.4%	10.9%	13.2%		8.7%		13.8%	8.3%	18.2%

Respiratory System	21.9%	20.7%	23.7%	22.4%	20.9%		24.2%		20.8%	20.0%	22.1%
Nose, Nasal Cavity and Middle Ear	60.8%	62.1%	58.6%	64.8%	66.6%	↑	62.0%		43.4%	42.4%	44.0%
Larynx	57.0%	57.3%	55.8%	59.1%	59.1%	↑	59.0%		53.0%	53.9%	49.3%
Lung and Bronchus	18.5%	15.8%	21.9%	19.0%	16.1%		22.4%		17.2%	15.1%	20.4%
Pleura	21.3%	13.0%	35.7%	26.1%	15.6%		40.2%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other Respiratory	46.5%	48.3%	43.5%	47.3%	47.7%		46.9%		41.5%	45.2%	34.7%
Bones and Joints	63.4%	59.0%	68.0%	65.2%	56.3%		72.0%		59.4%	60.5%	57.6%
Soft Tissue including Heart	63.3%	64.8%	61.1%	66.1%	66.8%		64.8%	↑	56.7%	60.3%	53.1%
Skin excluding Basal and Squamous	90.0%	88.3%	92.5%	90.5%	88.7%	↑	93.0%		76.8%	68.4%	83.2%
Melanoma of the Skin	90.5%	88.8%	92.9%	91.0%	89.3%	↑	93.5%	↑	63.6%	54.8%	70.0%
Other Non-Epithelial Skin	85.7%	83.0%	88.6%	84.5%	83.0%		86.4%		88.7%	79.7%	93.1%
Breast	86.6%	75.1%	86.6%	89.3%	77.4%		89.3%	↑	80.7%	71.5%	80.8%
Female Genital System	64.1%	0.0%	64.1%	67.9%	0.0%		67.9%	↑	55.5%	0.0%	55.5%
Cervix Uteri	63.9%	0.0%	63.9%	67.1%	0.0%		67.1%	↑	58.4%	0.0%	58.4%
Corpus and Uterus, NOS	73.8%	0.0%	73.8%	80.2%	0.0%		80.2%	↑	60.3%	0.0%	60.3%
Corpus Uteri	75.6%	0.0%	75.6%	81.5%	0.0%		81.5%	↑	62.8%	0.0%	62.8%
Uterus, NOS	21.4%	0.0%	21.4%	26.7%	0.0%		26.7%		14.3%	0.0%	14.3%
Ovary	44.3%	0.0%	44.3%	46.4%	0.0%		46.4%	↑	38.5%	0.0%	38.5%
Vagina	43.7%	0.0%	43.7%	43.1%	0.0%		43.1%		46.2%	0.0%	46.2%
Vulva	69.7%	0.0%	69.7%	71.1%	0.0%		71.1%		64.6%	0.0%	64.6%
Other Female Genital Organs	49.0%	0.0%	49.0%	52.2%	0.0%		52.2%		38.8%	0.0%	38.8%
Male Genital System	96.8%	96.8%	0.0%	97.9%	97.9%	↑	0.0%		95.0%	95.0%	0.0%
Prostate	97.0%	97.0%	0.0%	98.0%	98.0%	↑	0.0%		95.2%	95.2%	0.0%
Testis	96.8%	96.8%	0.0%	97.4%	97.4%		0.0%		93.2%	93.2%	0.0%
Penis	68.9%	68.9%	0.0%	73.3%	73.3%		0.0%		59.2%	59.2%	0.0%
Other Male Genital Organs	84.9%	84.9%	0.0%	94.7%	94.7%	↑	0.0%		61.3%	61.3%	0.0%
Urinary System	74.3%	74.8%	73.2%	75.3%	75.7%	↑	74.5%	↑	70.4%	70.9%	69.8%
Urinary Bladder	75.1%	76.9%	69.5%	77.0%	77.9%	↑	74.1%	↑	64.9%	71.0%	52.7%
Kidney and Renal Pelvis	74.6%	73.6%	76.2%	74.9%	74.4%	↑	75.8%		74.0%	71.4%	77.5%
Ureter	44.5%	43.3%	46.4%	45.9%	44.8%		47.5%		29.6%	29.0%	29.2%
Other Urinary Organs	46.1%	53.0%	33.7%	48.8%	52.8%		37.0%		40.3%	51.6%	27.9%
Eye and Orbit	75.3%	74.5%	76.1%	74.8%	75.5%		74.1%		80.6%	71.3%	87.9%
Brain and Other Nervous System	33.3%	31.8%	35.1%	32.1%	30.5%	↓	33.9%		37.3%	36.1%	38.7%
Brain	30.2%	29.5%	31.2%	29.2%	28.4%		30.1%		33.9%	33.7%	34.2%
Cranial Nerves Other Nervous System	77.7%	70.9%	83.0%	79.4%	71.8%		85.7%		74.2%	68.3%	77.9%
Endocrine System	96.3%	92.6%	97.6%	97.0%	94.2%	↑	98.1%		94.3%	86.3%	96.3%
Thyroid	98.1%	96.1%	98.7%	98.2%	96.0%		98.9%		97.4%	94.0%	97.9%
Other Endocrine including Thymus	64.7%	65.0%	63.7%	62.8%	64.9%		59.2%		66.8%	63.5%	70.1%
Lymphoma	71.0%	68.8%	73.5%	72.4%	71.1%	↑	74.0%	↑	66.2%	61.4%	71.4%
Hodgkin Lymphoma	85.0%	84.3%	85.8%	84.3%	85.0%		83.4%	↓	86.1%	82.1%	90.8%
Hodgkin - Nodal	85.7%	85.1%	86.1%	85.0%	85.8%		83.9%	↓	86.5%	82.7%	90.8%
Hodgkin - Extranodal	44.9%	41.5%	50.2%	44.6%	39.7%		50.2%		54.1%	54.1%	0.0%
Non-Hodgkin Lymphoma	68.8%	66.4%	71.6%	70.7%	69.1%	↑	72.7%	↑	61.8%	56.6%	67.4%
NHL - Nodal	66.5%	63.5%	70.1%	68.8%	66.3%	↑	71.9%	↑	57.5%	52.9%	62.9%
NHL - Extranodal	73.0%	72.0%	74.1%	74.5%	74.7%	↑	74.3%		68.8%	63.4%	73.7%
Myeloma	53.6%	52.7%	54.6%	54.2%	55.1%		52.9%		52.6%	49.2%	55.7%

Leukemia	62.0%	61.3%	62.8%	63.6%	62.2%	↑	65.3%	↑	56.6%	57.9%	55.0%
Lymphocytic Leukemia	80.6%	79.1%	82.7%	82.0%	80.3%	↑	84.4%	↑	73.7%	73.9%	73.3%
Acute Lymphocytic Leukemia	68.7%	66.4%	71.2%	70.4%	69.1%		71.8%		61.7%	58.3%	66.5%
Chronic Lymphocytic Leukemia	83.9%	82.3%	86.2%	84.9%	82.6%		88.1%	↑	78.5%	80.1%	75.8%
Other Lymphocytic Leukemia	78.1%	76.5%	80.9%	81.2%	79.9%	↑	83.7%		61.4%	58.5%	65.4%
Myeloid and Monocytic Leukemia	40.7%	38.5%	43.1%	39.7%	37.0%		43.1%		42.7%	41.5%	43.7%
Acute Myeloid Leukemia	25.5%	23.2%	28.0%	24.3%	20.7%		28.6%		28.1%	29.0%	27.5%
Acute Monocytic Leukemia	24.8%	29.7%	17.6%	22.3%	27.2%		16.0%		27.3%	28.8%	21.9%
Chronic Myeloid Leukemia	66.4%	62.7%	70.9%	65.1%	61.9%		69.0%		69.6%	64.1%	75.4%
Other Myeloid/Monocytic Leukemia	30.2%	33.2%	26.1%	29.2%	34.2%		22.5%		31.8%	25.3%	41.7%
Other Leukemia	51.8%	53.2%	50.1%	51.4%	53.0%		48.4%		51.3%	51.2%	50.5%
Other Acute Leukemia	29.1%	20.7%	35.8%	29.8%	23.6%		34.1%		25.7%	0.0%	40.5%
Aleukemic, Subleukemic and NOS	63.2%	70.8%	55.9%	63.3%	69.5%		55.3%		62.3%	71.1%	53.7%
Mesothelioma	8.5%	5.5%	15.1%	8.5%	6.7%		12.3%		8.0%	0.0%	23.3%
Kaposi Sarcoma	67.8%	68.4%	56.0%	84.6%	85.3%	↑	65.8%		52.0%	53.6%	0.0%
Miscellaneous	37.4%	36.1%	38.8%	38.9%	38.9%	↑	38.8%		33.1%	28.1%	37.9%

¹Except for urinary bladder (in situ and invasive), only invasive cases are included.

[^]The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly (p < 0.05) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2020^{1,2}

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	192,740	36,141	39,961	28,466	26,767	12,399	12,127	23,248	14,088
Oral Cavity and Pharynx	5,027	840	1,044	780	695	332	345	615	385
Esophagus	692	116	155	114	83	53	41	81	49
Stomach	1,544	346	298	223	206	86	108	190	89
Colon and Rectum	19,298	3,437	3,774	2,595	2,924	1,283	1,384	2,385	1,522
Liver and Intrahepatic Bile Duct	1,435	409	279	238	181	84	48	141	57
Pancreas	1,171	247	215	212	167	56	67	131	77
Larynx	2,003	375	407	301	301	127	123	247	123
Lung and Bronchus	9,071	1,790	1,696	1,302	1,359	595	582	1,046	706
Melanoma of the Skin	9,472	1,435	2,298	1,582	1,063	659	601	1,018	824
Breast	39,637	8,134	8,051	5,911	5,552	2,379	2,126	4,706	2,830
Cervix Uteri	2,394	477	443	293	337	174	157	339	175
Corpus and Uterus, NOS	5,959	1,142	1,140	802	839	381	398	805	453
Ovary	1,755	359	383	283	223	108	111	191	98
Prostate	45,607	8,264	10,413	6,050	6,287	2,876	2,763	5,676	3,279
Testis	1,737	330	366	252	240	131	126	182	112
Urinary Bladder	7,971	1,487	1,587	1,364	1,067	528	519	929	495
Kidney and Renal Pelvis	10,197	1,817	2,107	1,622	1,512	673	651	1,105	718
Brain and Other Nervous System	1,457	275	306	229	195	97	100	156	101
Thyroid	8,876	1,501	1,617	1,389	1,353	594	625	1,087	712
Hodgkin Lymphoma	1,878	360	359	302	251	122	136	223	126
Non-Hodgkin Lymphoma	8,401	1,629	1,635	1,337	1,163	608	542	957	533
Myeloma	2,442	496	540	361	266	133	132	327	189
Leukemia	5,169	818	992	828	716	389	347	659	418
Acute Lymphocytic Leukemia	738	125	157	119	105	55	40	86	49
Mesothelioma	128	30	31	25	14	12	6	^	^
Kaposi Sarcoma	195	89	41	13	16	9	^	17	^

¹ January 1, 2020, 20-Year Limited Duration Prevalence counts are based on 2020 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2019 and 2020 populations.

²Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 20 years (2000-2019). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 20 years (2000-2019).

³ Breast tumor includes both sexes. ⁴ Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers
Only, January 1, 2019^{1,2}

Site/Ages	All ages	0-20	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	192,747	3,265	14,657	23,492	50,491	62,904	35,471	9,996
Oral Cavity and Pharynx	5,027	46	281	726	1,655	1,539	641	225
Esophagus	692	^	9	50	181	253	163	38
Stomach	1,544	^	79	171	366	490	333	104
Colon and Rectum	19,299	48	827	2,134	5,555	5,978	3,635	1,257
Liver and Intrahepatic Bile Duct	1,435	43	25	68	428	584	239	52
Pancreas	1,171	^	60	89	266	388	272	95
Larynx	2,003	^	42	227	612	711	343	74
Lung and Bronchus	9,071	9	124	459	1,922	3,335	2,587	783
Melanoma of the Skin	9,473	108	1,394	1,488	2,203	2,247	1,536	624
Breast	39,637	6	2,387	7,138	10,964	11,383	6,508	2,047
Cervix Uteri	2,394	^	875	678	468	268	72	32
Corpus and Uterus, NOS	5,959	^	375	791	1,837	1,983	798	171
Ovary	1,755	48	249	282	455	423	227	71
Prostate	45,608	^	39	1,618	11,849	20,778	9,886	1,436
Testis	1,737	94	1,109	343	153	29	6	^
Urinary Bladder	7,971	8	162	497	1,609	2,688	2,215	847
Kidney and Renal Pelvis	10,197	164	566	1,394	2,726	3,204	1,782	453
Brain and Other Nervous System	1,458	530	376	191	156	132	61	18
Thyroid	8,876	159	2,279	1,926	2,133	1,593	671	122
Hodgkin Lymphoma	1,878	266	897	273	225	135	65	18
Non-Hodgkin Lymphoma	8,403	235	843	950	1,883	2,356	1,671	542
Myeloma	2,442	^	62	220	559	850	561	195
Leukemia	5,169	752	453	494	977	1,258	871	369
Acute Lymphocytic Leukemia	738	583	68	23	37	19	8	^
Mesothelioma	128	^	12	14	19	33	37	11
Kaposi Sarcoma	195	^	88	45	25	15	16	8

¹ January 1, 2020, 20-Year Limited Duration Prevalence. Populations were estimated by averaging 2019 and 2020 populations.

² Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 20 years (2000-2019). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 20 years (2000-2019).

³ Breast tumor includes both sexes.

⁴ Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2016-2020, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	124,262	132,455	93.8%
Oral Cavity and Pharynx	3,592	3,658	98.2%
Esophagus	1,251	1,290	97.0%
Stomach	1,799	1,839	97.8%
Small Intestine	870	882	98.6%
Colon and Rectum	11,759	12,077	97.4%
Colon excluding Rectum	8,134	8,402	96.8%
Rectum and Rectosigmoid Junction	3,625	3,675	98.6%
Liver	1,450	2,772	52.3%
Pancreas	3,409	3,968	85.9%
Larynx	1,392	1,412	98.6%
Lung and Bronchus	15,779	17,641	89.4%
Melanoma of the Skin	4,592	4,601	99.8%
Breast	18,271	18,439	99.1%
Corpus and Uterus, NOS	3,123	3,167	98.6%
Ovary	1,157	1,237	93.5%
Prostate	18,741	19,085	98.2%
Urinary Bladder	4,945	5,018	98.5%
Kidney and Renal Pelvis	5,671	6,255	90.7%
Brain and Other Nervous System	1,280	1,471	87.0%
Thyroid	3,417	3,431	99.6%
Hodgkin Lymphoma	658	664	99.1%
Non-Hodgkin Lymphoma	4,843	4,977	97.3%
Myeloma	1,894	2,282	83.0%
Leukemia	3,390	3,697	91.7%
Mesothelioma	291	306	95.1%
Kaposi Sarcoma	107	111	96.4%

¹Case counts represent the total combined number of cases for the 5-year period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.